CHANTICLEER HOLDINGS INC |
End-of-day quote
Other stock markets
|
||
| - USD | - |
|
| Mar. 11 | Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street | MT |
| Mar. 11 | Top Premarket Gainers | MT |
Financials (USD)
| Sales 2024 * | 117K | Sales 2025 * | - | Capitalization | 5.4M |
|---|---|---|---|---|---|
| Net income 2024 * | -7M | Net income 2025 * | -21M | EV / Sales 2024 * | 46.2 x |
| Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1
x | P/E ratio 2025 * |
-
| Employees | - |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 0% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
| - | - | ||
| 53 | - | ||
| 72 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| 62 | - | ||
| 60 | - | ||
| 75 | - |
Sonnet Biotherapeutics Holdings Inc, formerly Chanticleer Holdings, Inc., an oncology-focused biotechnology company. The Company is developing targeted biologic drugs with enhanced single or bispecific mechanisms.
Sector
Restaurants & Bars
Calendar
2024-05-07
- Q2 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +28.34% | 10.48B | |
| +15.05% | 8.54B | |
| +2.47% | 2.24B | |
| +11.79% | 2.1B | |
| -15.12% | 2.02B | |
| -0.37% | 1.8B | |
| +6.10% | 1.64B | |
| -2.01% | 1.47B | |
| -9.00% | 1B |
